24/7 Market News Snapshot 12 May, 2025 – Annexon, Inc. Common Stock (NASDAQ:ANNX)

May 12, 2025

DENVER, Colo., 12 May, 2025 (www.247marketnews.com) – (Nasdaq:ANNX) are discussed in this article.
Annexon, Inc. (Nasdaq:ANNX), a leading biopharmaceutical company, is experiencing a significant bullish movement in the market, with shares opening at $1.72 and currently trading around $1.742, reflecting an increase of approximately 8.87% from the previous session’s close of $1.60. This surge indicates heightened investor interest, as evidenced by a trading volume of 2.07 million shares, showcasing robust market activity that could suggest further upward momentum. Technical indicators are favorable, potentially signaling a trend reversal that could attract both short-term traders and long-term investors.

In parallel with its stock performance, Annexon is advancing its clinical programs aimed at addressing unmet needs in neuroinflammatory diseases. The company is preparing for an FDA meeting in the second quarter of 2025 regarding tanruprubart, a pioneering monoclonal antibody designed to treat Guillain-Barré Syndrome (GBS). This treatment has shown promising results in enhancing functional recovery in patients across multiple trials, positioning it as a potential first-in-class therapy for this condition.

Additionally, Annexon has commenced the open-label FORWARD study slated for the same quarter, which aims to streamline the treatment experience for healthcare providers and patients through tanruprubart’s single-infusion approach. The firm is also advancing its other innovative therapies, including the ANX007 for dry age-related macular degeneration with geographic atrophy, which is expected to finalize enrollment in the Phase 3 ARCHER II trial by the third quarter of 2025, with pivotal data anticipated by late 2026.

Moreover, Annexon is making progress with ANX1502, an oral C1s inhibitor targeting cold agglutinin disease, with proof-of-concept trials expected to conclude by mid-2025. As of March 31, 2025, the company boasts a strong cash position of $263.7 million, ensuring that it is well-positioned to continue its innovative research initiatives throughout 2026.

Related news for (ANNX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.